Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: A transfer conveyor assembly for a screening apparatus includes at least one transfer conveyor that is oriented transversely with respect to a feed direction of the screening apparatus and is configured to receive material from at least one respective screen deck of the screening apparatus. At least one intermediate transfer conveyor is positioned with respect to at least one further screen deck of the screening apparatus to receive material from the at least one further screen deck to feed material to a position away from the at least one transfer conveyor in a discharge direction of the screening apparatus.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.

Abstract: A transfer conveyor assembly for a screening apparatus includes at least one transfer conveyor that is oriented transversely with respect to a feed direction of the screening apparatus and is configured to receive material from at least one respective screen deck of the screening apparatus. At least one intermediate transfer conveyor is positioned with respect to at least one further screen deck of the screening apparatus to receive material from the at least one further screen deck to feed material to a position away from the at least one transfer conveyor in a discharge direction of the screening apparatus.

Abstract: A mobile screening apparatus includes a support chassis. The support chassis is configured for carrying at least one screening assembly having a top screen deck and at least one further screen deck below the top screen deck. At least at least one primary feed mechanism is configured for arrangement in communication with any one or more of the top and further screen decks to feed material to be screened onto said any one or more of the top and further screen decks.

Abstract: This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostrate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, R3, R4, M1, M2, X, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, and wherein at least one of M2 or L2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: Example embodiments relate to a rotatable gravity feeding shelf unit having a bracket onto which a rotatable shelf is arranged. The shelf is arranged having an inclination angle for providing gravity feeding in a forward direction in a display position when a front side of the shelf is accessible. The shelf unit further includes a tilting device arranged for providing tilting of the plane of rotation of the shelf during rotation, thereby controlling the inclination angle of the shelf.

Abstract: A mobile screening apparatus includes a support chassis. The support chassis is configured for carrying at least one screening assembly having a top screen deck and at least one further screen deck below the top screen deck. At least at least one primary feed mechanism is configured for arrangement in communication with any one or more of the top and further screen decks to feed material to be screened onto said any one or more of the top and further screen decks.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer, stereoisomer or deuterated analogue thereof, wherein X, R, R1, R2, R3, R4, M1, M2, L1, L2, J1, J2, a1, a2, b1 and b2 are as defined herein, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.

Abstract: A shelf assembly for products to be placed in a limited space, which at least is limited in depth by a rear boundary surface and laterally by lateral surfaces. The shelf assembly consists of a shelving section with a front and a rear, which shelving section comprises a plurality of gravity-feeding shelves and a base plate. The shelving section is placed on a shelving section support and arranged on the same to be rotatable about an axis, which is arranged by a first engaging means, which is placed on the base plate and rotatably engaged with a second engaging means, which is placed on the shelving section support. The rear of the shelving section is in the refill position located further away from the rear boundary surface than is the front of the shelving section in the display position. Moreover, the shelving section is rotatable substantially within the limited space.